Clinical Research Directory
Browse clinical research sites, groups, and studies.
Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada
Sponsor: Neurocrine Biosciences
Summary
This study will evaluate long-term safety and tolerability of valbenazine in participants with chorea associated with Huntington Disease (HD) who participated in Study NBI-98854-HD3006 (NCT04400331) in Canada.
Official title: Open-Label Study of Valbenazine for the Treatment of Chorea Associated With Huntington Disease in Canada
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
7
Start Date
2024-04-24
Completion Date
2026-04
Last Updated
2026-04-09
Healthy Volunteers
No
Conditions
Interventions
Valbenazine
vesicular monoamine transporter 2 (VMAT2) inhibitor
Locations (3)
Neurocrine Clinical Site
Vancouver, British Columbia, Canada
Neurocrine Clinical Site
Ottawa, Ontario, Canada
Neurocrine Clinical Site
Toronto, Ontario, Canada